Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JV-GL1 periorbital application in glaucoma or ocular hypertension
NCT04761705Phase 2Suspended
- Sponsor
- JeniVision
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PGN 9856-isopropyl ester in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by JeniVision. Primary endpoint: Intraocular Pressure at Day 28. Started Mar 2021; status: suspended.
02
Drugs
PGN 9856-isopropyl ester
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04761705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761705.